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Abstract The recombinant phage antibody system pCANTAB
5E has been used to display functionally active leech-derived
tryptase inhibitor (LDTI) on the tip of the filamentous M13
phage. A limited combinatorial library of 5.2U104 mutants was
created with a synthetic LDTI gene, using a degenerated
oligonucleotide and the pCANTAB 5E phagemid. The mutations
were restricted to the P1^P4P positions of the reactive site.
Fusion phages and appropriate host strains containing the
phagemids were selected after binding to thrombin and DNA
sequencing. The variants LDTI-2T (K8R, I9V, S10, K11W,
P12A), LDTI-5T (K8R, I9V, S10, K11S, P12L) and LDTI-10T
(K8R, I9L, S10, K11D, P12I) were produced with a Sacchar-
omyces cerevisiae expression system. The new inhibitors, LDTI-
2T and -5T, prolong the blood clotting time, inhibit thrombin (Ki
302 nM and 28 nM) and trypsin (Ki 6.4 nM and 2.1 nM) but not
factor Xa, plasma kallikrein or neutrophil elastase. The variant
LDTI-10T binds to thrombin but does not inhibit it. The relevant
reactive site sequences of the thrombin inhibiting variants showed
a strong preference for arginine in position P1 (K8R) and for
valine in P1P (I9V). The data indicate further that LDTI-5T
might be a model candidate for generation of active-site directed
thrombin inhibitors and that LDTI in general may be useful to
generate specific inhibitors suitable for a better understanding of
enzyme-inhibitor interactions.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
The actions of thrombin are central to the hemostasis of
higher organisms and human beings [1]. Thrombin exhibits
both pro- and anti-coagulant e¡ects. Its three-dimensional
structure reveals an unusually deep and narrow active site
cleft which is the major determinant for its restricted substrate
speci¢city [2,3]. The catalytic activity of thrombin is regulated
physiologically by serpins such as antithrombin III, heparin
cofactor II, protease nexin I and by the general protease scav-
enger K2-macroglobulin [4]. In addition, heterologous protein-
type thrombin inhibitors are described, such as hirudin [5],
haemadin [6], rhodniin [7], bothrojaracin [8], triabin [9] and
ornithodorin [10]. These speci¢c and selective inhibitors are
present in hematophagous parasites where they prevent clot-
ting of sucked blood. The best studied thrombin inhibitor is
hirudin from the medical leech Hirudo medicinalis [5]. The
three-dimensional structural determination of its complex
with thrombin [11] as well as other three-dimensional struc-
tures of thrombin complexes with rhodniin [12] and ornitho-
dorin [10] revealed and con¢rmed a two-site interaction mech-
anism of these protein-type inhibitors with thrombin. This is
characterized by a strong interaction between the reactive site
of the inhibitor and the active site cleft of thrombin as well as
by extensive electrostatic interactions of various exosites of
the inhibitors and of the thrombin [13].
Leech-derived tryptase inhibitor (LDTI) is a Kazal-type
serine proteinase inhibitor of tryptase, trypsin and chymotryp-
sin. The appropriate Ki values are in the nM range [14]. The
small molecule consists of 46 amino acid residues and shows
high similarity to the speci¢c thrombin inhibitor rhodniin and
to the plasmin and trypsin inhibitor bdellin B-3 [15]. But
thrombin and plasmin are inhibited only very weakly by
LDTI, 12% and 30%, at a concentration of 0.2 WM, respec-
tively [14]. Recombinant LDTI (r-LDTI) is equivalent to iso-
lated native material [16] and was used for elucidation of the
three-dimensional structure in solution. r-LDTI shows a typ-
ical Kazal-type inhibitor fold as described earlier for other
ovomucoid inhibitors by Bode and Huber [17] but it has a
small internal deletion at the N-terminus [18]. The crystal
structure of the rLDTI-bovine trypsin complex con¢rmed
the structure in solution [19] and proved the typical sub-
strate-like ’canonical’ interaction with trypsin as well as the
inhibition model of ’small’ serine proteinase inhibitors postu-
lated by Laskowski and Kato [20].
Combinatorial mutations of peptides and proteins and their
display on the tips of ¢lamentous bacteriophages became an
important tool for the production and screening of protein
variants with altered binding a⁄nities in the last decade. Sev-
eral phage libraries have been created and used in di¡erent
ways, for example to identify new ligands for receptors [21], to
de¢ne substrates for enzymes [22], to optimize binding sites in
hormones [23] or to select new, high a⁄nity proteinase inhib-
itors [24^29]. The display of antigenic peptides and of antigen
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binding domains seems to be the most e¡ective application of
this technology [30^32].
We have evaluated the antibody expression and display
system pCANTAB 5E with the cysteine proteinase inhibitor
chicken cystatin earlier [33] and present data here on expres-
sion of the tryptase inhibitor LDTI, on the construction of a
restricted combinatorial phage/phagemid library, on screening
thrombin inhibitors and on inhibition kinetics. In a parallel
approach, we have constructed and expressed new bivalent r-
LDTI thrombin inhibitors by structure-based protein design.
There, the reactive site loop of LDTI was trimmed by cassette
mutagenesis to ¢t into thrombin’s narrow active site cleft and
the C-terminus of the inhibitor was prolonged with an acidic
linker peptide which binds to the ¢brinogen exosite of throm-
bin [34]. The results presented here open the possibility to
create new monovalent thrombin reactive site inhibitors by
phage display.
2. Materials and methods
2.1. Materials
The recombinant phage antibody system (pCANTAB 5E) and de-
tection module were purchased from Pharmacia and used as described
in the instruction manual. All reagents and methods were used or
carried out as described by Auerswald et al. [16].
2.2. LDTI cloning into pCANTAB 5E
A LDTI gene was obtained by polymerase chain reaction (PCR)
ampli¢cation using the LDTI cloning vector pRM 3.1.10 [16], the
forward PPEAKI 5P-AAA ATT AAC TGG CCC AGC AGG CCA
AGA AGG TTT GCG CAT GCC CAA AG-3P and the reverse prim-
er: PPEAKII 5P-AAA AGG AAA ATG CGG CCG CGT TTA AAA
TAC CGG TTG GAC AAG AAA C-3P from MWG-Biotech
(Munich, Germany). The underlined sequences represent the recogni-
tion sites for S¢I and NotI, respectively, both were used for insertion
of the PCR product into the phagemid vector pCANTAB 5E.
2.3. Construction of LDTI mutant library
The correct DNA sequence of the ampli¢ed LDTI gene was con-
¢rmed using S1 and S6 primers for pCANTAB 5E. The new vector
was named pAT 13.1.8 LDTI and expressed on the tips of phages or
alternatively in the periplasma of Escherichia coli using standard mo-
lecular cloning methods. A degenerate oligonucleotide (LOOP4) was
synthesized with several mutations. It contains the nucleotide se-
quence NNSDBB (N = A/T/C/G; S = G/C; B = C/G/T and D = A/G/
T) which codes for a restricted pool of amino acids at the positions
P1^P4P [35] of the inhibitor. A population of complementary DNA
strands was constructed using the LOOP4 oligonucleotide and the
backward primer PPEAK with Taq polymerase (see Fig. 1). The re-
sulting double stranded material was cleaved with SphI and NsiI and
ligated into dephosphorylated phagemid vector pAT 13.1.8 missing its
small SphI^NsiI cassette. The mixture of ligation products was used to
transform E. coli TG1 cells (K12(lac-pro), supE, thi, hsdD5/FP,
traD36, proAB, lacIq, lacZvM15) and to create the library.
2.4. Selection of LDTI variants binding thrombin
Transformed E. coli TG1 cells harboring the phagemids were grown
at 30‡C in 2UYT medium containing 200 Wg ampicillin (Amp)/ml and
2% (w/v) glucose up to an optical density of A550 = 0.5^0.7, helper
phages (M13KO7) were added (multiplicity of infection (moi) = 100),
in order to produce fusion phages and growth was continued for 1 h
at 37‡C. The fermentation broth was centrifuged, bacteria were col-
lected and resuspended in 2UYT fresh medium (200 Wg Amp/ml and
50 Wg kanamycin (Kan)/ml) and grown for 12^15 h, at 37‡C. The
broth was centrifuged, the pellet discarded and the fusion phage par-
ticles (supernatant) were used for repetitive selection by a⁄nity bind-
ing to bovine thrombin, applying an ELISA-like assay [33]. After the
second round of selection, bound fusion phages were eluted and used
for transfection of E. coli cells. Thirty colonies were grown to amplify
phage particles and ¢nally the constructs pAT15.1.2.T, pAT15.1.5T
and pAT15.1.10T were selected and used for further analyses.
2.5. Subcloning of LDTI variant genes and expression in
Saccharomyces cerevisiae
A secretory yeast expression system (pVT102U-K and S. cerevisiae
strain S-78, kindly provided by T. Vernet, Montreal, Que., Canada)
was used for production of LDTI variants. Therefore, fragments of
pAT15.1.2T, -5T and -10T were ampli¢ed and modi¢ed by PCR. The
forward primer used (5P-CCCAGCAGGCCTCTAGATAAAA-
GAAAGAAGGTTTGCGCATGCCC-3P) encodes the C-terminal
end of the alpha mating factor signal sequence containing the cleavage
site for KEX2 protease as well as the N-terminus of the LDTI variant
whereas the reverse primer used (5P-GGCCGCGAAGCTTAT-
Fig. 1. Primary structure of LDTI, schematic representation of the pCANTAB 5E-LDTI construct (pAT 13.1.8.) and DNA sequences of
LOOP4 and PPeak. A: Amino acid sequence of LDTI; the reactive site positions P1^P4P are boxed. B: Schematic representation of the impor-
tant parts of phagemid pAT13.1.8: P lac, lactose promoter; gIII signal, signal sequence of the gene III product; gene minor coat protein III
(gpIII); number in brackets, base pair positions of pCANTAB 5E; DNA sequences of the degenerated oligonucleotide LOOP4 (N = A/T/C/G;
S = G/C; B = C/G/T and D = A/G/T; and of the the primer PPeak.
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TAGTTTAAAATACCGGTTGGACAAGAACC-3P) encodes the C-
terminus of LDTI. The expression cassettes were ligated with XbaI/
HindIII-cleaved and dephosphorylated pVT102U-K vectors. The three
resulting yeast expression vectors were used to transform S. cerevisiae
strains S-78 [36], separately. Standard yeast cultivation and expression
experiments were carried out (pre-culture 2^3 days, 100 ml SD(+)
medium; main culture 4 days with 900 ml fresh YED-medium at
28‡C at 220 rpm) with S-78 strains x pAT16.1.2T, pAT17.1.5T and
pAT18.1.10T. During cultivation the cell density (OD 700) was deter-
mined daily, the pH adjusted to 6.0 with NaOH when necessary and
10 ml of yeast extract stock solution (50% w/v) and 30 ml of glucose
(50% w/v) were added daily. Thrombin inhibitory activity was ana-
lyzed according to Strube et al. [6].
2.6. Puri¢cation of LDTI variants
Transformed yeast cells were harvested after 144 h cultivation
(6000Ug, 20 min, 4‡C). The supernatants were applied to DEAE-
Sephadex A-50 (batch form) and bound proteins were eluted with
0.05 M Tris-HCl, pH 8.0, 0.5 M NaCl. The trypsin inhibitory activ-
ities were measured according to Erlanger et al. [37]. The material was
puri¢ed further by a⁄nity chromatography on trypsin-Sepharose pre-
pared according to the manufacturer’s instructions (Pharmacia). The
LDTI-variants were analyzed by SDS-PAGE [38] and by protein se-
quencing (473A, Applied Biosystems GmbH, Weiterstadt, Germany).
2.7. Determinations of equilibrium dissociation constants (Ki)
The equilibrium dissociation constants of complexes between the
variants and bovine thrombin, bovine trypsin, human factor Xa, hu-
man plasma kallikrein or human neutrophil elastase were determined
using the method described by Bieth [39]. Brie£y, the serine proteases
were incubated with di¡erent concentrations of the variants in 0.1 M
Tris-HCl (pH 8.0, 0.1% Triton X-100, 37‡C) and the residual enzyme
activities were measured after addition of chromogenic substrates:
S2238 (Chromogenix), Ac.Phe-Arg-pNa (kind gift from Dr. L. Julia-
no, Departamento de Bio¢sica, UNIFESP-EPM), S2222 (Chromoge-
nix), S2302 (Chromogenix) and MeoSuc.Ala-Ala-Pro-Val-pNa (Cal-
biochem) for the enzymes above, respectively. Apparent Ki values
were calculated by ¢tting the steady-state velocities to the equation
for tight-binding inhibitor using a non-linear regression analysis [40].
2.8. Clotting time-thrombin time (TT)
Human blood was collected from healthy volunteers (15 ml) and
transferred to a tube containing 1.5 ml 3.8% sodium citrate. Eryth-
rocytes, platelets and leukocytes were removed by centrifugation
(1450Ug, 15 min, room temperature). The plasma was transferred
to a new tube and stored on ice. The TT prolongation was determined
by adding di¡erent concentrations of protease inhibitors to 200 Wl of
normal plasma and 100 Wl of 2.5 U of thrombin (Sigma, St. Louis,
MO, USA). The clotting times were measured and the data were
compared with data from normal plasma.
3. Results
The synthetic LDTI gene from pRM 3.1.10 [16] was ampli-
¢ed and ligated into pCANTAB 5E. E. coli transformants
were selected after DNA sequencing. The phagemid pAT
13.1.8. contains the correct LDTI sequence. This construct
allows expression of the trypsin-binding fusion protein
LDTI-protein III on the tip of the ¢lamentous phage. The
binding activities of the resulting recombinant phages were
detected after 103-fold enrichment by biopanning against im-
mobilized trypsin. As a negative control M13 phages were
used. The trypsin-binding LDTI phages react with anti M13
antibody as expected (data not shown).
The phagemid pAT 13.1.8 was used to construct a library
of LDTI variants carrying mutations at the reactive site posi-
tions P1^P4P. The strategy of library construction is shown
schematically in Fig. 1. The mutated double-stranded frag-
ments were ligated into the LDTI gene and phagemids and
phages were produced. The library titer was 5.2U104 colony
forming unit (cfu)/2 ml. The library was ampli¢ed to 3.5U109
cfu/ml and used to identify thrombin-binding LDTI variants.
Therefore, LDTI fusion phages were immobilized by biopan-
ning on thrombin-coated microtiter plates. Each selection
round was monitored by phage titration (dilution and plating
on SOBAG plates containing Amp); the enrichment was only
10-fold. In total, 30 colonies were isolated carrying the appro-
priate phagemids and used to produce fusion phages. Finally,
¢ve colonies were selected and the phagemid DNAs of them
were partially sequenced. Three DNA sequences were detected
(5P-CGCGTCTTGTCCCTGG-3P ; 5P-CGGGTTTTGTCCC-
Table 1
Comparison of the amino acid sequence of the reactive site region of LDTI variants selected to thrombin with the cleavage site regions of nat-
ural substrates and the reactive site of a speci¢c inhibitor of thrombin
P3 P2 P1 P1P P2P P3P P4P P5P P6P Ki (nM)
Substrates cleavage sitesa
Fibrinogen A 14G V R G P R V V E
Fibrinogen B 12S A R G H R P L D
Thrombin receptor 39D P R S F L L R N
Protein C 167D P R L I D G K M
Factor XIII 36V P R G V N L Z Z
Factor V 707G I R S F R N S S
Factor VIII 738G P R S F S Q N S
Optimal cleavage sequenceb (F) P R S F R ?
Rhodniin domain 1c 8C P H A L H R V C 3.8d
LDTI wild-type 6C P K I L K P V C s 300
LDTI 2T 6C P R V L W A V C 302.0
LDTI 5T (3 times) 6C P R V L S L V C 28.0
LDTI 10T 6C P R L L D I V C n.i.
n.i. : not inhibited.
aCleavage sites of thrombin substrates [42]. Rhodniin domain 1 sequence [7].
bOptimal cleavage sequence for thrombin [19].
cRhodniin domain 1 sequence [7].
dM. Otte (unpublished data).
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TC-3P ; 5P-AGGGTCTTGTCGTTG-3P) encoding RVLSL
(LDTI-5T); the DNA sequence (5P-CGCGTCTTGTGGG-
CC-3P) encoding RVLWA (LDTI-2T) and (5P-CGGTTG-
TTGGACATC-3P) for RLLDI (LDTI-10T) were found only
once (Table 1). All constructs showed the amino acid codons
(CGC; CGG; AGG) for arginine at position 8 in P1. It is well
known that thrombin substrates are cleaved preferentially
after an arginine which binds to the S1 subsite (Table 1).
In order to characterize the inhibition pro¢le of the LDTI
variants it was necessary to produce more material, but it was
di⁄cult to generate enough fusion phages with the system
used. An alternative periplasmic expression approach in E.
coli was also not successful, although the suppliers of the
pCANTAB 5E system are favoring this route. Therefore,
DNA fragments containing LDTI-2T, -5T and -10T were
subcloned, expressed and secreted with the pVT102U-K S.
cerevisiae system. The expression levels of these variants
were between 15 and 45 mg/l as calculated by trypsin inhib-
ition assays and titrated trypsin as standard enzyme. It was
shown before that LDTI [14,19] binds and inhibits trypsin in
an equimolar ratio. LDTI-2T, -5T and -10T were isolated
from the yeast supernatant, puri¢ed by ion-exchange
(DEAE-Sephadex) and a⁄nity chromatography (trypsin-
Sepharose). The puri¢ed material of all three variants showed
only one band after SDS-PAGE (data not shown). The mo-
lecular masses of the LDTI variants were around 5000 Da,
which is close to the theoretical value for LDTI wild-type
(4737.6 Da). The expected N-terminal amino acids of the
three variants including the mutated positions P1^P4P were
con¢rmed by amino acid sequencing (14, 23 and 23 amino
acid residues for variants 2T, 5T and 10T, respectively). The
inhibition of human factor Xa, human plasma kallikrein and
human neutrophil elastase by the three variants were tested up
to a concentration of 0.5 WM of the inhibitors, but the three
serine proteinases are not inhibited at these conditions. Fi-
nally, the equilibrium dissociation constants (Ki) of complexes
between the LDTI variants and bovine trypsin or bovine
thrombin were determined (Table 2). The variants LDTI-2T
and LDTI-5T are strong trypsin and thrombin inhibitors with
Ki values of 6.4 nM and 2.1 nM for trypsin and 302 nM and
28 nM for thrombin, respectively. Both variants increase the
clotting time of human blood triggered by thrombin (TT) in a
concentration-dependent manner. The prolongation of TT by
LDTI-2T and LDTI-5T is 1.8- and 2.0-fold at 0.5 WM, respec-
tively. The LDTI wild-type and LDTI-10T have no e¡ect on
blood clotting (Fig. 2). The LDTI-10T is the weakest inhibitor
of the three variants, its Ki with trypsin is 12 nM. A Ki value
with thrombin could not be determined under the conditions
used, although the appropriate phages bind to thrombin.
4. Discussion
It is well known that several protein-type thrombin inhib-
itors interact not only with the active site of thrombin but also
with its various exosites such as the ¢brinogen exosite, the
heparin binding site or the antithrombin III binding site.
This makes thrombin an enzyme whose interaction with in-
hibitors (and also with substrates) may be improved by muta-
tions at several sites. Our aim was to evaluate a combinatorial
mutation approach with LDTI and to optimize only a single,
monovalent contact region which binds to the active site of
thrombin thus causing inhibition. This approach was sup-
ported by: (a) structural inspection of LDTI and other throm-
bin inhibitors, (b) the successful phage display of another
proteinase inhibitor [33] and (c) the generation of combina-
tory libraries of proteinase inhibitors reported in the litera-
ture. Markland and coworkers [41] e.g. described the success-
ful creation of inhibitor variants for plasmin and plasma
kallikrein using the ¢rst Kunitz domain of the human lipo-
protein associated coagulation inhibitor (LACI-DI), although
a comparable approach to mutate a small Kunitz-type inhib-
itor BPTI into a thrombin inhibitor failed [41].
Our experiments show that the Kazal-type serine proteinase
inhibitor LDTI can be presented in a functionally active form
on phage surfaces. This result con¢rms experiments with other
inhibitors performed earlier such as aprotinin (BPTI) [24],
plasminogen activator inhibitor (PAI-1) [25], tissue factor in-
hibitor (Kunitz-domain) [26] and hirudin [29]. Furthermore, it
demonstrates that a very small protein (46 amino acids long)
can be produced in a stable and active form.
The pCANTAB 5E system allowed the production and se-
Table 2
Apparent equilibrium dissociation constants (Ki) for LDTI and its
variants with selected serine proteases. Ki values (nM)
Enzyme LDTI 2T 5T 10T
Bovine trypsin 0.9 6.4 2.1 12
Bovine thrombin s 300a 302 28 n.i.
Human factor Xa n.i. n.i. n.i. n.i.
Human plasma kallikrein n.i. n.i. n.i. n.i.
Human neutrophil elastase n.i. n.i. n.i. n.i.
n.i. : not inhibited.
aData from Morenweiser et al. [34].
Fig. 2. Prolongation of blood clotting time-TT in normal human
plasma. The inhibitor concentrations are plotted versus the prolon-
gation factor of TT upon initiation by thrombin (0.5 U). The inhib-
ition assay was performed by addition of inhibitors to the plasma
before the enzyme. The clotting time to normal plasma is 16.5 s.
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lection of mutated phagemids and fusion phages. The positive
bindings were detected by ELISA techniques although the
expression of the LDTI variants was low. Up to 30 LDTI
variants were identi¢ed and ¢ve phagemids were selected.
The sequences of all mutants showed at position P1 the codon
for arginine. This arginine residue is most typical in thrombin
substrates and thrombin inhibitors and is important for bind-
ing to the complementary S1 subsite [2,3,42]. The pCANTAB
5E system failed to produce su⁄cient amounts of fusion
phages or of periplasmic LDTI variants for detailed inhibition
studies. Therefore, the LDTI variants were subcloned, ex-
pressed and puri¢ed using the pVT102U/K-Saccharomyces
cerevisiae system. The variant LDTI-10T binds to thrombin,
but does not inhibit it. We do not know if this variant is
cleaved or if it would inhibit at higher concentrations. An
explanation for its weak binding could be the isoleucine res-
idue at position P1P, the bulky side chain of which may cause
steric hindrance and obstruction during access to the active
site of thrombin as suggested by van de Locht et al. [12] ear-
lier. A comparably poor interaction is found with the Denver
antithrombin III mutant, carrying leucine in P1P instead of
serine [43]. Other site-directed mutagenesis experiments
showed corresponding results with appropriate amino acid
substitutions in the P1P position [44].
The variants LDTI-2T and -5T inhibit thrombin activity
with Ki values in the nM range and prolong the clotting TT
remarkably. Both variants contain the smaller valine residue
at P1P, which contributes positively to binding to the small S1P
pocket at the thrombin active site cleft created by the so called
’60 loop’ [12]. The small di¡erence determined in a⁄nity to
thrombin between LDTI-5T and LDTI-2T can be explained
by serine in P3’ (LDTI-5T) which is more favorable than the
tryptophan residue in -2T. The sequence RVL (P1^P2P),
present in both variants, is found also in a native thrombin
inhibitor from the hematophagous insect Triatoma infestans
(Tanaka, unpublished results).
In principle, the variants 2T and 5T showed 1000^10 000-
fold weaker inhibitory activity against thrombin when com-
pared to hirudin or rhodniin [7]. However, we have to keep in
mind that the LDTI-variants are monovalent inhibitors bind-
ing only to the active site of thrombin and not to an addi-
tional exosite. The single domain 1 of rhodniin, which is prob-
ably the best monovalent inhibitor to compare with, inhibits
thrombin only 8-fold stronger than LDTI-5T (M. Otte, per-
sonal communication)[45].
In conclusion, our results have increased the application
range of the phage display system to a greater array of potent
macromolecular inhibitors. The ¢ndings indicate that LDTI is
a useful tool in generating new protease inhibitors and may
cause a better understanding of enzyme-inhibitor interactions.
The LDTI-5t variant could be used as a lead molecule for
construction of monovalent thrombin inhibitors.
Acknowledgements: We thank Prof. T. Vernet (Biotechnology Re-
search Institute, Montreal, Que., Canada), Prof. Cheng-Wu Chi,
Prof. Zhang You-shaing and Prof. Hu Hong-ming (Shangai Institute
of Biochemistry, China) for providing the expression vector
pVT102U/a and S. cerevisiae S 78, R. Mentele for the N-terminal
amino acid sequencing. This work was supported by: FAPESP-
Proc.95/9256-8 and CNPq (Brazil), SFB 469 A-3 Sonderforschungs-
bereich der Ludwig-Maximilians-Universita«t, Mu«nchen, the Volkswa-
genstiftung 71 045 and the Bundesministerium fu«r Bildung, Wissen-
schaft, Forschung und Technologie BMBFT 0310931 (Germany).
A.S.T. was supported by Conselho Nacional de Desenvolvimento
Cient|¤¢co Tecnolo¤gico (CNPq).
References
[1] Davie, E.W., Fujikawa, K. and Kisiel, W. (1991) Biochemistry
30, 10364^10370.
[2] Bode, W., Mayr, I., Baumann, U., Huber, R., Stone, S.R. and
Hofsteenge, J. (1989) EMBO J. 8, 3467^3475.
[3] Bode, W., Turk, D. and Karshikov, A. (1992) Protein Sci. 1,
426^471.
[4] Olson, S.T. and Bjo«rk, I. (1992) in: Thrombin Structure and
Function (Berliner, L.J., Ed.), pp. 159^217, Plenum Press, New
York.
[5] Walsmann, P. and Markwardt, F. (1981) Pharmazie 36, 653^660.
[6] Strube, K-H., Kro«ger, B., Bialojan, S., Otte, M. and Dodt, J.
(1993) J. Biol. Chem. 268, 8590^8595.
[7] Friedrich, T., Kro«ger, B., Bialojan, S., Lemaire, H.G., Ho«¡ken,
H.W., Reuschenbach, P., Otte, M. and Dodt, J. (1993) J. Biol.
Chem. 268, 16216^16222.
[8] Zingali, R.B., Jandrot-Perrus, M., Guillin, M-C. and Bon, C.
(1993) Biochemistry 32, 10794^10802.
[9] Noeske-Jungblut, C., Haendler, B., Donner, P., Alagon, A., Pos-
sani, L. and Schleuning, W-D. (1995) J. Biol. Chem. 270, 28629^
28634.
[10] Van de Locht, A., Stubbs, M., Bode, W., Friedrich, T., Bolll-
schweiler, C., Ho«¡ken, W. and Huber, R. (1996) EMBO J. 15,
6011^6017.
[11] Rydel, T.J., Ravichandran, K.G., Tulinsky, A., Bode, W., Huber,
R., Roitsch, C. and Fenton, J.W. (1990) Science 249, 277^280.
[12] Van de Locht, A., Lamba, D., Bauer, M., Huber, R., Friedrich,
T., Kro«ger, B., Ho«¡ken, W. and Bode, W. (1995) EMBO J. 14,
5149^5157.
[13] Stubbs, M.T. and Bode, W. (1995) Trends Biochem. Sci. 20, 23^
28.
[14] Sommerho¡, C.P., So«llner, C., Mentele, R., Piechottka, G.P.,
Auerswald, E.A. and Fritz, H. (1994) Biol. Chem. Hoppe-Seyler
375, 685^694.
[15] Fink, E., Rehm, H., Gippner, C., Bode, W., Eulitz, M., Mach-
leidt, W. and Fritz, H. (1986) Biol. Chem. Hoppe-Seyler 367,
1235^1242.
[16] Auerswald, E.A., Morenweiser, R., Sommerho¡, C.P., Piechott-
ka, G.P., Eckerskorn, C., Gu«rtler, L.G. and Fritz, H. (1994) Biol.
Chem. Hoppe-Seyler 375, 695^703.
[17] Bode, W. and Huber, R. (1992) Eur. J. Biochem. 204, 433^451.
[18] Mu«hlhahn, P., Czisch, M., Morenweiser, R., Habermann, B.,
Engh, R.A., Sommerho¡, C.P., Auerswald, E.A. and Holak,
T.A. (1994) FEBS Lett. 355, 290^296.
[19] Stubbs, M.T., Morenweiser, R., Stu«rzebecher, J., Bauer, M.,
Bode, W., Huber, R., Piechottka, G.P., Matschiner, G., Som-
merho¡, C.P., Fritz, H. and Auerswald, E.A. (1997) J. Biol.
Chem. 272, 19931^19937.
[20] Laskowski, Jr.M. and Kato, I. (1980) Annu. Rev. Biochem. 49,
593^626.
[21] O’Neil, K.T., Hoess, R.H., Jackson, S.A., Ramachandran, N.S.,
Mousa, S.A. and Degrado, W.F. (1992) Proteins 14, 509^515.
[22] Matthews, J.D. and Wells, J.A. (1993) Science 260, 1113^1117.
[23] Lowman, H.B. and Wells, J.A. (1993) J. Mol. Biol. 234, 564^578.
[24] Roberts, B.L., Markland, W., Ley, A.C., Kent, R.B., White,
D.W., Guterman, S.K. and Ladner, R.C. (1992) Proc. Natl.
Acad. Sci. USA 89, 2429^2433.
[25] Pannekoek, H., van Meijer, M., Schleef, R.R., Loskuto¡, D.J.
and Barbas III, C.R. (1993) Gene 128, 135^140.
[26] Dennis, M.S. and Lazarus, R.A. (1994) J. Biol. Chem. 269,
22129^22136.
[27] Wang, C-I., Yang, Q. and Craik, C.S. (1995) J. Biol. Chem. 270,
12250^12256.
[28] Ro«ttgen, P. and Collins, J. (1995) Gene 164, 243^250.
[29] Wirsching, F., Opitz, T., Dietrich, R. and Schwienhorst, A.
(1997) Gene 204, 177^184.
[30] Barbas III, C.F., Kang, A.S., Lerner, R.A. and Benkovic, S.J.
(1991) Proc. Natl. Acad. Sci. USA 88, 7978^7982.
[31] Marks, J.D., Hoogenboom, H.R., Bonnert, T.P., McCa¡erty, J.,
Gri⁄ths, A.D. and Winter, G. (1991) J. Mol. Biol. 222, 581^597.
[32] Hoogenboom, H.R., de Bru|«ne, A.P., Hufton, S.E., Hoet, R.M.,
FEBS 22550 1-9-99
A.S. Tanaka et al./FEBS Letters 458 (1999) 11^16 15
Arends, J.W. and Roovers, R.C. (1998) Immunotechnology 4, 1^
20.
[33] Tanaka, A.S., Sampaio, C.A.M., Fritz, H. and Auerswald, E.A.
(1995) Biochem. Biophys. Res. Commun. 214, 389^395.
[34] Morenweiser, R., Auerswald, E.A., Van de Locht, A., Fritz, H.,
Stu«rzebecher, J. and Stubbs, M.T. (1997) J. Biol. Chem. 272,
19938^19942.
[35] Schechter, I. and Berger, A. (1967) Biochem. Biophys. Res. Com-
mun. 27, 157^162.
[36] Becker, D.M. and Guartante, L. (1991) Methods Enzymol. 194,
182^187.
[37] Erlanger, B.F., Kokowsky, N. and Cohen, E. (1961) Arch. Bio-
chem. Biophys. 95, 271^278.
[38] Laemmli, U.K. (1970) Nature 227, 680^685.
[39] Bieth, J.G. (1980) Bull. Eur. Physiopathol. Respir. 16, 183^
195.
[40] Morrison, J.F. (1969) Biochim. Biophys. Acta. 185, 269^286.
[41] Markland, W., Ley, A.C. and Ladner, R.C. (1996) Biochemistry
35, 8045^8067.
[42] Stubbs, M.T. and Bode, W. (1993) Thromb. Res. 69, 1^58.
[43] Stephens, A.W., Thalley, B.S. and Hirs, C.H.W. (1987) J. Biol.
Chem. 262, 1044^1048.
[44] Theunissen, H.J.M., Dijkema, R., Grootenhuis, P.D.J., Swinkels,
J.C., Poorter, T.L., Carati, P. and Visser, A. (1993) J. Biol.
Chem. 268, 9035^9040.
[45] Otte, M. (1997) Untersuchung der Thrombin-Rhodniin Wechsel-
wirkung mit Hilfe gentechnologisch hergestellter Rhodniinvar-
ianten, Thesis, Technische Hochschule, Darmstadt.
FEBS 22550 1-9-99
A.S. Tanaka et al./FEBS Letters 458 (1999) 11^1616
